Literature DB >> 18333200

Hilar cholangiocarcinoma: diagnosis and staging.

William Jarnagin1, Corinne Winston.   

Abstract

Cancer arising from the proximal biliary tree, or hilar cholangiocarcinoma, remains a difficult clinical problem. Significant experience with these uncommon tumors has been limited to a small number of centers, which has greatly hindered progress. Complete resection of hilar cholangiocarcinoma is the most effective and only potentially curative therapy, and it now clear that concomitant hepatic resection is required in most cases. Simply stated, long-term survival is generally possible only with an en bloc resection of the liver with the extrahepatic biliary apparatus, leaving behind a well perfused liver remnant with adequate biliary-enteric drainage. Preoperative imaging studies should aim to assess this possibility and must evaluate a number of tumor-related factors that influence resectability. Advances in imaging technology have improved patient selection, but a large proportion of patients are found to have unresectable disease only at the time of exploration. Staging laparoscopy and (13)fluoro-deoxyglucose positron emission tomography (FDG-PET) may help to identify some patients with advanced disease; however, local tumor extent, an equally critical determinant of resectability, may be underestimated on preoperative studies. This paper reviews issues pertaining to diagnosis and preoperative evaluation of patients with hilar biliary obstruction. Knowledge of the imaging features of hilar tumors, particularly as they pertain to resectability, is of obvious importance for clinicians managing these patients.

Entities:  

Year:  2005        PMID: 18333200      PMCID: PMC2043098          DOI: 10.1080/13651820500372533

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  15 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

2.  Preoperative evaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: comparison with intraarterial digital subtraction angiography.

Authors:  Moon-Gyu Lee; Kwang Bo Park; Yong Moon Shin; Hyun Ki Yoon; Kyu Bo Sung; Myung Hwan Kim; Sung Gyu Lee; Eun Mee Kang
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

3.  Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography.

Authors:  L H Schwartz; F V Coakley; Y Sun; L H Blumgart; Y Fong; D M Panicek
Journal:  AJR Am J Roentgenol       Date:  1998-06       Impact factor: 3.959

4.  Late development of bile duct cancer after sphincteroplasty: a ten- to twenty-two-year follow-up study.

Authors:  K Hakamada; M Sasaki; M Endoh; T Itoh; T Morita; M Konn
Journal:  Surgery       Date:  1997-05       Impact factor: 3.982

5.  Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience.

Authors:  Y Nimura; J Kamiya; S Kondo; M Nagino; K Uesaka; K Oda; T Sano; H Yamamoto; N Hayakawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

6.  Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.

Authors:  U Broomé; R Olsson; L Lööf; G Bodemar; R Hultcrantz; A Danielsson; H Prytz; H Sandberg-Gertzén; S Wallerstedt; G Lindberg
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

7.  Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.

Authors:  R Kluge; F Schmidt; K Caca; H Barthel; S Hesse; P Georgi; A Seese; D Huster; F Berr
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

8.  Malignant hepatic hilar tumors: can ultrasonography be used as an alternative to angiography with CT arterial portography for determination of resectability?

Authors:  L E Hann; Y Fong; C D Shriver; J F Botet; K T Brown; D S Klimstra; L H Blumgart
Journal:  J Ultrasound Med       Date:  1996-01       Impact factor: 2.153

9.  Pathological aspects of cholangiocarcinoma.

Authors:  K Weinbren; S S Mutum
Journal:  J Pathol       Date:  1983-02       Impact factor: 7.996

10.  Outcomes after curative resections of cholangiocarcinoma.

Authors:  D M Nagorney; J H Donohue; M B Farnell; C D Schleck; D M Ilstrup
Journal:  Arch Surg       Date:  1993-08
View more
  16 in total

1.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 2.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

3.  Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases.

Authors:  Stefan Buettner; Jeroen L A van Vugt; Marcia P Gaspersz; Robert J S Coelen; Eva Roos; Tim A Labeur; Georgios A Margonis; Cecilia G Ethun; Shishir K Maithel; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley A Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Jan N M IJzermans; Thomas M van Gulik; Timothy M Pawlik; Bas Groot Koerkamp
Journal:  HPB (Oxford)       Date:  2017-05-23       Impact factor: 3.647

4.  Volatile organic compounds in bile for early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis: a pilot study.

Authors:  Udayakumar Navaneethan; Mansour A Parsi; Vennisvasanth Lourdusamy; Amit Bhatt; Norma G Gutierrez; David Grove; Madhusudhan R Sanaka; Jeffrey P Hammel; Tyler Stevens; John J Vargo; Raed A Dweik
Journal:  Gastrointest Endosc       Date:  2014-12-12       Impact factor: 9.427

5.  Risk factors for hilar cholangiocarcinoma: a case-control study in China.

Authors:  Wen-Ke Cai; Hui Sima; Ben-Dong Chen; Guang-Shun Yang
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

6.  Minimally invasive approaches to extrapancreatic cholangiocarcinoma.

Authors:  Andrew A Gumbs; Nicolas Jarufe; Brice Gayet
Journal:  Surg Endosc       Date:  2012-08-28       Impact factor: 4.584

7.  Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings.

Authors:  Kyle Hodges; Lindsey Kennedy; Fanyin Meng; Gianfranco Alpini; Heather Francis
Journal:  Transl Gastrointest Cancer       Date:  2012-02-08

8.  Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Authors:  Kawin Leelawat; Sompong Sakchinabut; Siriluck Narong; Jerasak Wannaprasert
Journal:  BMC Gastroenterol       Date:  2009-04-30       Impact factor: 3.067

9.  Changing perspectives in the assessment of resectability of hilar cholangiocarcinoma.

Authors:  Thomas M van Gulik; Dirk J Gouma
Journal:  Ann Surg Oncol       Date:  2007-04-24       Impact factor: 5.344

10.  Endoscopic ultrasound of the hepatoduodenal ligament and liver hilum.

Authors:  Malay Sharma; Chittapuram Srinivasan Rameshbabu; Christoph F Dietrich; Praveer Rai; Raghav Bansal
Journal:  Endosc Ultrasound       Date:  2018 May-Jun       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.